Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

Human Pathology

Volumn 38, Issue 11, 2007, Pages 1703-1713

  Huang, Hong Ying ^a   Shariat, Shahrokh F ^d   Sun, Tung Tien ^a,b   Lepor, Herbert ^a   Shapiro, Ellen ^a   Hsieh, Jer Tsong ^d   Ashfaq, Raheela ^d   Lotan, Yair ^d   Wu, Xue Ru ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Prognosis; Progression; Transitional cell carcinoma; Uroplakin

Indexed keywords

BCG VACCINE; CYCLIN D1; MITOMYCIN C; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; UROPLAKIN;

ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CELL CYCLE REGULATION; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENT DISEASE; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH; UNIVARIATE ANALYSIS;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS; UROTHELIUM;

EID: 35348887132     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.04.003     Document Type: Article

References (38)

1. American Cancer Society. Cancer facts and figures (2006), American Cancer Society, Atlanta (Ga) 4
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
3. Dalbagni G., Presti J., Reuter V., Fair W.R., and Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 342 (1993) 469-471
4. Dinney C.P., McConkey D.J., Millikan R.E., et al. Focus on bladder cancer. Cancer Cell 6 (2004) 111-116
5. Koss L.G. Natural history and patterns of invasive cancer of the bladder. Eur Urol 33 (1998) 2-4
6. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
7. Cohen S.M. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 30 (2002) 663-671
8. Koss L.G. Tumors of the bladder. Diagnostic cytology of the urinary tract: with histopathologic and clinical correlations (1996), Lippincott-Raven, Philadelphia 71-139
9. Spiess P.E., and Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130 (2006) 844-852
10. Madeb R., and Messing E.M. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 22 (2004) 86-92
11. Grossman H.B., and Dinney C.P. If cystectomy is insufficient, what is an urologist to do?. Urol Oncol 21 (2003) 475-478
12. Wu X.R., Lin J.H., Walz T., et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 269 (1994) 13716-13724
13. Deng F.M., Liang F.X., Tu L., et al. Uroplakin IIIb, a urothelial differentiation marker, dimerizes with uroplakin Ib as an early step of urothelial plaque assembly. J Cell Biol 159 (2002) 685-694
14. Koss L.G. The asymmetric unit membranes of the epithelium of the urinary bladder of the rat. An electron microscopic study of a mechanism of epithelial maturation and function. Lab Invest 21 (1969) 154-168
15. Hicks R.M. The fine structure of the transitional epithelium of rat ureter. J Cell Biol 26 (1965) 25-48
16. Wu X.R., Medina J.J., and Sun T.T. Selective interactions of UPIa and UPIb, two members of the transmembrane 4 superfamily, with distinct single transmembrane-domained proteins in differentiated urothelial cells. J Biol Chem 270 (1995) 29752-29759
17. Tu L., Sun T.T., and Kreibich G. Specific heterodimer formation is a prerequisite for uroplakins to exit from the endoplasmic reticulum. Mol Biol Cell 13 (2002) 4221-4230
18. Hu P., Deng F.M., Liang F.X., et al. Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. J Cell Biol 151 (2000) 961-972
19. Truschel S.T., Wang E., Ruiz W.G., et al. Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. Mol Biol Cell 13 (2002) 830-846
20. Moll R., Wu X.R., Lin J.H., and Sun T.T. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol 147 (1995) 1383-1397
21. Olsburgh J., Harnden P., Weeks R., et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 199 (2003) 41-49
22. Sun T.T. Altered phenotype of cultured urothelial and other stratified epithelial cells: implications for wound healing. Am J Physiol Renal Physiol 291 (2006) F9-F21
23. Lobban E.D., Smith B.A., Hall G.D., et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 153 (1998) 1957-1967
24. Yuasa T., Yoshiki T., Isono T., Tanaka T., and Okada Y. Molecular cloning and expression of uroplakins in transitional cell carcinoma. Adv Exp Med Biol 539 (2003) 33-46
25. Lotan Y., Gupta A., Shariat S.F., et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23 (2005) 6533-6539
26. Bircan S., Candir O., and Serel T.A. Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 73 (2004) 201-208
27. Allred D.C., Clark G.M., Elledge R., et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85 (1993) 200-206
28. Shariat S.F., Ashfaq R., Sagalowsky A.I., and Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 37 (2006) 1568-1576
29. Parker D.C., Folpe A.L., Bell J., et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 27 (2003) 1-10
30. Sandberg A.A. Cytogenetics and molecular genetics of bladder cancer: a personal view. Am J Med Genet 115 (2002) 173-182
31. Russell P.J., Sauter G., Hung T.-T., and Waldman F.M. Cytogenetics of urothelial neoplasia. In: Lerner S.P., Schoenberg M.P., and Sternberg C.N. (Eds). Textbook of bladder cancer (2006), Taylor & Francis, Boca Raton 123-136
32. Cowled P., Kanter I., Leonardos L., and Jackson P. Uroplakin Ib gene transcription in urothelial tumor cells is regulated by CpG methylation. Neoplasia 7 (2005) 1091-1103
33. Koss L.G. Some ultrastructural aspects of experimental and human carcinoma of the bladder. Cancer Res 37 (1977) 2824-2835
34. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 (2001) 731-737
35. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., and Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5 (2005) 899-904
36. Habuchi T., Marberger M., Droller M.J., et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66 (2005) 64-74
37. Kurahashi T., Hara I., Oka N., Kamidono S., Eto H., and Miyake H. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 11 (2005) 3773-3777
38. Seraj M.J., Thomas A.R., Chin J.L., and Theodorescu D. Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. Clin Cancer Res 7 (2001) 1516-1522